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coronary microvascular dysfunction and cardiac mortality in patients with diabetes mellitus. 8 Importantly, the MR has been implicated in many components of this cascade. 9, 10 Specifically, MR activation promotes cardiovascular inflammation, oxidative stress, endothelial dysfunction, impaired coronary flow reserve, and cardiac fibrosis. [11] [12] [13] [14] [15] [16] In addition, recent reports reveal a role for the MR in enhancing proinflammatory immune cell phenotypes, including classically activated M1 macrophages and T-helper 17 lymphocytes. 17, 18 Based on these results, we hypothesized that MR signaling contributes significantly to obesity-associated DD and that MR blockade will interrupt disease progression, providing the first viable therapeutic avenue for DD in this specific patient population.
To test this hypothesis, we treated Zucker obese (ZO) rats with a blood pressure-independent low dose of the MR antagonist spironolactone (LSp). 19 Previous work from our group and others demonstrates that ZO rats develop pronounced DD with coronary microvascular dysfunction. [20] [21] [22] In addition to examining the effect of MR blockade in ZO rats, a role for the MR in the onset of and mechanisms underlying DD was examined in Sprague-Dawley (SD) rats treated with a subpressor dose of the MR agonist aldosterone.
Methods
For detailed description, see Methods in the online-only Data Supplement.
Results

Insulin Resistance and Kidney Injury Were Not Altered by LSp Treatment in ZO Rats
Compared with Zucker lean (ZL), ZO rats exhibited metabolic syndrome components including increased body weight, epididymal fat pad mass, insulin resistance (HOMA-IR [homeostatic model assessment of insulin resistance]), fasting plasma leptin, glucose, insulin, cholesterol, and triglyceride but not corticosterone (Table  S2 in ) beginning at 29 weeks of age for 3 weeks had no effect on these parameters or serum potassium in ZO-LSp rats. Plasma aldosterone was reduced in ZO, but not ZO-LSp, rats versus ZL (Table S2) involving reduced plasma angiotensin II, despite increased plasma renin activity (Figure S1A and S1B). ZO rats exhibited proteinuria that was unchanged by LSp, and urinary sodium excretion was similar across all groups (Table S2) .
MR Inhibition Normalized Obesity-Related Cardiac DD Independent of Blood Pressure
Systolic blood pressure was similar between all groups (Table  S2) . Compared with ZL, cardiac MR mRNA expression was unchanged in ZO but reduced in ZO-LSp, whereas mRNA expression of the MR target gene lipocalin-2 was increased in ZO rats regardless of treatment (Figure S1C ). Consistent with our previous report, 22 ZO rats exhibited abnormal diastolic function versus ZL (Figure 1A-1C ; Table S3 ) and increased myocardial performance index, a heart rate-independent measure of diastolic and systolic function ( Figure 1D ). Myocardial performance index is increased because of abnormal diastolic function indicated by abnormal diastolic septal wall motion (decreased E′/A′; Figure 1A ), decreased propagation velocity of mitral inflow (Figure 1B) , increased isovolumic relaxation time (Figure 1C) , and increased LV filling pressure (increased E/E′; Table S3 ). Fractional shortening and ejection fraction were unchanged, indicating normal systolic function in ZO rats (Table S3 ). The abnormal diastolic parameters were largely ameliorated in ZO-LSp rats, indicating that MR antagonism treated established obesity-associated cardiac DD via blood pressure-independent mechanisms.
MR Inhibition With LSp Reduces Cardiac Fibrosis, But Not Hypertrophy, in ZO Rats
Given the well-described profibrotic action of MR signaling, we examined cardiac hypertrophy and fibrosis after MR inhibition. Compared with ZL, ZO rats exhibited LV hypertrophy, by LV-to-tibia length ratio (Figure 2A ) and septal/ posterior wall thicknesses (Table S3 ) that was unchanged by LSp treatment. Cardiomyocyte area tended to be increased in ZO (P=0.07) and was increased in ZO-LSp versus ZL (Figure 2A ). However, elevated cardiac interstitial and periarterial fibrosis in ZO rats was reduced by LSp ( Figure 2B ). Conversely, cardiac mRNA expression of collagen I, collagen III, and transforming growth factor-β1 tended to be or was reduced in ZO rats regardless of treatment ( Figure S1D ). Thus, the normalization of diastolic function in obesity by MR inhibition involves reduced cardiac fibrosis without reduced hypertrophy.
LSp Restores Coronary Arteriolar Endothelial Function in ZO Rats
We examined coronary microvascular function, an important regulator of cardiac perfusion, as this could underlie the normalization of diastolic function in ZO-LSp rats. Coronary dysfunction before LSp treatment was confirmed in a subset of rats at 14 to 16 weeks of age, in that ZO rats had impaired coronary dilation to insulin but not ACh ( Figure S2 ). Similar to previous studies, 20,21 ZO coronaries exhibited reduced ACh-and insulin-induced vasodilation at 32 weeks of age ( Figure 3A) . Constriction to the thromboxane analog U46619 was similar in all Zucker groups ( Figure S3A ). LSp treatment Figure S3B ). Insulin vasodilation ( Figure 3A ) and insulin-stimulated aortic endothelial Akt(Thr 308 ) phosphorylation ( Figure 3B ) were improved by LSp. Last, arterioles from Zucker rats were not remodeled (similar wall:lumen ratios), LSp treatment did not reduce the obesity-associated increase in arteriolar elastic modulus (stiffness; Figure S3C ), and dilation to sodium nitroprusside (NO donor) was unchanged, confirming normal smooth muscle NO sensitivity ( Figure S3D ) and indicating endothelial cell dysfunction. Together, these data indicate that MR inhibition in ZO rats improves coronary microvascular function in concert with reduced cardiac fibrosis and improved diastolic function.
MR Antagonism Abrogates Obesity-Associated Elevations in Cardiac Oxidative Stress
To further explore potential mechanism(s) underlying reduced cardiac fibrosis and improved diastolic function in ZO-LSp rats, we examined cardiac oxidative stress. Cardiac oxidative stress was elevated in ZO versus ZL rats (Figure 4A and 4B) . Specifically, cardiac ROS production and cardiac 3-nitrotryrosine were increased in ZO rats (Figure 4A and 4B), whereas NADPH oxidase activity tended to be elevated (P=0.07; Figure 4A ) versus ZL. Each of these, particularly NADPH oxidase activity, was reduced in ZO-LSp rats ( Figure 4A and 4B). Thus, MR antagonism abrogates obesity-associated cardiac oxidative stress in conjunction with improved diastolic function and reduced fibrosis.
LSp Treatment Attenuates Obesity-Related Visceral Adipose Inflammation
Because of the role of adipose inflammation and adiposederived cytokines in obesity-related disease processes, we considered whether the modulation of cardiac oxidative stress was associated with systemic alterations in adipose inflammation/cytokines. Circulating levels of the proinflammatory cytokines monocyte chemoattractant protein-1 (MCP-1), tumor A, Vasodilator responses of coronary arterioles from Zucker rats to endothelium-dependent dilators acetylcholine and insulin and (B) insulin-stimulated Akt (Thr necrosis factor-α, and the oxidative stress marker thiobarbituric acid reactive substances were increased in ZO rats and treatment with LSp reduced circulating MCP-1 ( Figure 5A ). Similarly, proinflammatory gene expression was increased in epididymal fat from ZO rats ( Figure 5B ). Specifically, expression of MCP-1, tumor necrosis factor-α, vascular cell adhesion molecule-1, intercellular adhesion molecule-1, and NADPH oxidase subunits (p22phox/p47phox) were increased in ZO versus ZL rats. LSp treatment normalized some, but not all, adipose inflammatory genes ( Figure 5B). Along with increased inflammatory gene expression, ZO rats exhibit marked adipose immune cell infiltration indicated by increased immune marker mRNAs for M1 macrophages, assessed by the generalized macrophage marker F4/80 and M1 marker CD11c, as well as T cells, assessed by CD4 and the regulatory T (Treg) cell marker FoxP3 ( Figure 5C ). The presence of macrophage mRNAs was reduced in ZO-LSp rats ( Figure 5C ). Together, these data demonstrate that the MR plays a role in obesityrelated adipose inflammation and immune cell recruitment.
MR Antagonism Induces an Anti-Inflammatory Shift of Cardiac Immune Cell Markers in ZO Rats
We next examined whether reduced cardiac fibrosis and oxidative stress in ZO-LSp rats was associated with an antiinflammatory shift in the cardiac immune cell phenotype by examining cardiac immune cell mRNAs. Compared with ZL rats, ZO rats exhibited unchanged cardiac mRNAs for MCP-1 (gene and protein; Figure S4A ) and vascular cell adhesion molecule-1 while tumor necrosis factor-α was reduced and intercellular adhesion molecule-1 was elevated, indicating cardiac inflammation ( Figure S4B ). Immune marker mRNAs for total macrophages (F4/80), proinflammatory M1 macrophages (CD11c), anti-inflammatory M2 macrophages (CD163), T cells (CD4), or Treg cells (FoxP3) were unchanged in ZO versus ZL (Figure 6 ). After LSp treatment, however, ZO-LSp rats exhibited increased mRNA expression for anti-inflammatory M2 macrophages (CD163) and Treg cells (FoxP3; Figure 6 ). These data suggest that the improvement in obesity-related cardiac DD, fibrosis, vascular function, and oxidative stress after MR antagonism is associated with an anti-inflammatory shift of cardiac immune cell marker genes. ) in SD rats for 3 weeks beginning at 8 weeks of age raised plasma aldosterone but not blood pressure (Table S4) . SD rats infused with aldosterone (SD-Aldo) exhibited cardiac diastolic, but not systolic, dysfunction (Table S5; Figure S5A ) without cardiac/ cardiomyocyte hypertrophy ( Figure S5B ) but elevated cardiac Figure S5C ). SD-Aldo rats also exhibited impaired coronary arteriolar endotheliumdependent vasodilation to acetylcholine and insulin ( Figure  S5D ) in conjunction with increased cardiac oxidative stress markers thiobarbituric acid reactive substances and 3-nitrotryrosine ( Figure S5E ). Similarly, SD-Aldo rats exhibited increased systemic inflammation (plasma MCP-1 and tumor necrosis factor-α; Figure S6A ) and oxidative stress (plasma thiobarbituric acid reactive substances; Figure S6B ); however, SD-Aldo rats did not exhibit elevated epididymal adipose inflammatory gene expression ( Figure S6C ). Thus, subpressor MR agonism by aldosterone recapitulated many of the cardiovascular, but not adipose, consequences of obesity, suggesting differential MR signaling in the presence of comorbidities.
Aldosterone Infusion Recapitulates
Discussion
In summary, we have demonstrated that MR antagonism with a blood pressure-independent dose of spironolactone is able to reverse established obesity-related DD. Treatment with LSp largely normalized obesity-associated increases in cardiac fibrosis, oxidative stress, coronary endothelial dysfunction, and systemic and adipose inflammation/immune cell recruitment in ZO rats in vivo. In addition, LSp treatment promoted an anti-inflammatory shift in cardiac immune cell mRNAs involving increased Treg and M2 macrophage markers in the absence of changes in systemic metabolic parameters, serum potassium, or kidney injury. Importantly, the benefit of LSp occurred with reduced circulating aldosterone in this model of normotensive obesity, indicating a limitation of plasma aldosterone as a marker of MR activation. Similar improvement in cardiac phenotype with MR blockade was previously reported in a model of low-aldosterone salt-sensitive hypertension. 23 Reduced circulating aldosterone in the ZO rat can be accounted for by a significant reduction in plasma angiotensin II, despite increased plasma renin activity indicating reduced hepatic angiotensinogen production or reduced angiotensin-converting enzyme activity in this model. It is likely that cardiac MR activation occurs mainly via corticosterone (unchanged in ZO rats) because of its equivalent affinity for the MR and the possibility of local cardiac and adipose aldosterone production cannot be ruled out. To our knowledge, this is the first study to demonstrate that MR antagonism effectively treats DD in a model of obesity and insulin resistance, and these results reveal novel deleterious roles for MR in the development of obesity-associated cardiovascular dysfunction.
It is established that the benefit of MR antagonists in the treatment of systolic heart failure 24,25 involves suppression of cardiac collagen accumulation. 26, 27 Our data support a similar cardiac antifibrotic role of MR antagonism in the context of obesity-related DD in agreement with small human studies demonstrating reduced circulating markers of fibrosis with MR blockade in patients with obesity. 4, 5 In the ZO rat, this likely involves increased collagen degradation or decreased production after LSp because collagen gene expression was reduced in these rats. An important departure between this study and those in patients with obesity, however, relates to the lack of effect of LSp to reduce cardiac hypertrophy in ZO rats, whereas LV mass index/cardiac dimensions were reduced by spironolactone in patients with obesity. 4, 5 The lack of reduction in hypertrophy in ZO-LSp rats involves increased cardiomyocyte area, suggesting that reduced hypertrophy is not necessary for improved cardiac diastolic function in obesity and insulin resistance, further supporting the importance of reduced fibrosis underlying the clinical benefit of MR antagonists in DD.
The link between coronary perfusion (ie, coronary arteriolar function) and cardiac diastolic function is well established. For instance, in healthy dogs, reduced coronary perfusion increases cardiac isovolumic relaxation time (ie, impaired cardiac relaxation). 28 In agreement with previous work, 20 ,21 ZO rats demonstrated impaired coronary arteriolar vasodilation at 14 to 16 weeks of age that was normalized by LSp beginning at 29 weeks of age, and this may explain the improvement in coronary flow reserve in patients with type 2 diabetes mellitus after MR blockade. 13 Our data suggest that improved endothelium-dependent vasodilation after LSp involves non-NO pathways (ie, prostacyclin/ EDHF) and direct improvement in endothelial insulin signaling without improved arteriolar stiffness. To our knowledge, this is the first report of MR-dependent modulation of endothelial insulin signaling. Our data are consistent with a recent study demonstrating that knockout of the leukocyte/ endothelial MR prevented aortic endothelial dysfunction in diet-induced obesity involving modulation of cyclooxygenase-1-dependent pathways. 29 Future studies are necessary to fully delineate MR-dependent modulation of endotheliumdependent vasodilator pathways in obesity. Regardless, the improvement in coronary endothelium-dependent vasodilation by LSp is clinically relevant because coronary endothelial dysfunction and impaired coronary flow reserve are independently predictive of acute/long-term cardiovascular events. 8, 30 MR-dependent modulation of inflammatory pathways may be a central component of obesity-related cardiac dysfunction underlying the therapeutic effect of MR antagonists. Our data demonstrate that MR antagonism attenuated systemic and adipose inflammation and immune cell recruitment, particularly involving M1 macrophages, similar to previous mouse studies. 29, 31, 32 In addition, we demonstrate that in the presence of cardiac inflammation (ie, increased intercellular adhesion molecule-1 mRNA) but not obesity-related alteration of cardiac immune cell marker mRNAs, LSp treatment increased cardiac mRNAs for anti-inflammatory M2 macrophages and Treg cells. Recent evidence demonstrates a role of MR signaling as a direct, physiologically relevant modulator of macrophage polarization and of the T-helper 17/Treg axis. 17, 18, 33 Together with our data demonstrating abrogated cardiac, but not systemic, oxidative stress after LSp treatment, these data suggest an important pathogenic role of local MR signaling in obesity-related cardiovascular dysfunction. Thus, we speculate that the anti-inflammatory influence of these cell types may underlie the improved cardiac phenotype after LSp treatment in ZO rats; however, future mechanistic studies addressing this issue are necessary.
Interrogation of the systemic effects of MR activation in this study revealed several additional surprising findings that warrant further examination. First, LSp treatment did not improve kidney injury/proteinuria or increase serum potassium in the ZO rat, suggesting that MR activation either does not contribute to kidney injury in this model or that our dose of spironolactone is too low to sufficiently block renal MR. Indeed, the dose used in this study inhibits ≈35% of radiolabeled aldosterone binding in vivo in the rat. 34 In addition, our results suggest that MR signaling in various tissues is context-dependent because aldosterone infusion in healthy SD rats recapitulated some (cardiac/coronary dysfunction, cardiac/systemic inflammation/oxidative stress), but not all (adipose inflammation), consequences of pathological MR signaling revealed by LSp treatment of ZO rats.
Perspectives
We have demonstrated that LSp, too low to cause significant changes in serum potassium or blood pressure, treats established obesity-associated DD. This benefit of MR blockade involves reduced cardiac fibrosis, improved coronary microvascular function, and attenuated cardiac oxidative stress and systemic inflammation. Furthermore, our data suggest a novel anti-inflammatory shift of cardiac immune cell markers after LSp in obesity that warrants further study. In DD caused by etiologies in which the inciting factors are different, MR antagonists may not be beneficial. This contextdependent role of MR signaling in DD may have contributed to the recent negative results of the TOPCAT trial. 1 Because MR signaling plays an integral role in the development of DD in obesity, further study on MR antagonists to treat DD specifically in patients with insulin resistance and obesity is warranted. What Is New?
• Treatment with the mineralocorticoid receptor (MR) antagonist spironolactone reverses established cardiac diastolic dysfunction in obese, insulin resistant rats and is associated with reduced cardiac oxidative stress and fibrosis, attenuated systemic and adipose inflammation, and improved cardiac immune cell markers.
• MR blockade improved coronary microvascular endothelial function in obesity via improved nitric oxide-independent vasodilation and restored insulin-dependent signaling to Akt with no change in arteriolar structure/ stiffness.
• The benefit of MR antagonism occurred, despite reduced circulating aldosterone highlighting a limitation of using aldosterone as a surrogate for MR signaling.
What Is Relevant?
• Cardiac diastolic dysfunction, the major cardiac defect in diastolic heart failure, is common in patients with obesity and insulin resistance although no clear evidence-based therapies exist.
• Low-dose MR blockade with spironolactone normalized cardiac and coronary vascular function independent of changes in blood pressure, systemic insulin resistance, kidney injury, and serum potassium in a rat model. ) for 21 days beginning at 29 wk of age. This dose of spironolactone was chosen based on previous evidence that it does not reduce blood pressure in a RAAS-dependent model of hypertension 1 and that anti-androgenic and progestogenic effects are absent while ~35% of in vivo aldosterone binding is inhibited in the rat 2 . Zucker lean (ZL) rats received placebo pellets. To ensure a treatment design, the age of pellet implantation was chosen based on published evidence that ZO rats exhibit established defects in cardiac diastolic function and coronary endothelium-dependent vasodilation by 28 wk of age [3] [4] [5] . Early impairment of coronary insulin-induced dilation was examined in a subset of untreated (no pellet implantation) ZL and ZO rats euthanized at 14-16 wk of age. Twenty-four hour urine collection was performed during the final week of treatment in all animals. SD rats were randomly assigned to vehicle (SD) or aldosterone (SD-Aldo) treatment. Under isoflurane anesthesia (2-4% in 100% O2), rats were implanted with osmotic mini-pumps (Alzet model 2004, Cupertino, CA) containing either vehicle (ethanol in saline) or aldosterone (50 µg·kg -1 ·day -1 ) for 21 days beginning at 8 wk of age. SD rats were maintained on a normal sodium diet (0.28% in chow with no additional salt in drinking water). This dose of aldosterone was chosen based on previous evidence demonstrating no change in blood pressure by radiotelemetry and aortic endothelial cell dysfunction 6 and SD, rather than ZL, rats were chosen for the infusion studies as this is a common strain utilized in this type of experiment. Animals were fasted 5 hours prior to euthanization, anesthetized with isoflurane (2-4% in 100% O2), blood was subsequently collected from the abdominal aorta, processed to plasma and serum, and frozen at -80°C. Animals were euthanized by exsanguination.
Blood pressure measurement. Blood pressure was determined by tail-cuff (Coda 8, Kent Scientific, Torrington, CT) during the final week of treatment. Rats were acclimated to restraints and tail cuffs for 3 days. Blood pressure was determined on the fourth day with 10-25 (minimum of 5) cuff inflations averaged for each animal.
Echocardiography. Two-dimensional echocardiography (GE Vivid i, GE Healthcare, Wauwatosa, WI) was performed under isoflurane anesthesia (2-4% in 100% O2) in apical long and parasternal short axis views at the level of the left ventricular (LV) mid-cavity or the mitral inflow with M-mode and pulsed wave (PW) Doppler, according to Hoit 7 and as previously described 5 . Briefly, in M-mode, aortic (Ao) and left atrial (LA) diameters were obtained in long axis while LV septal and posterior wall thicknesses in diastole (SWTd and PWTd, respectively), LV internal diameter at end diastole and end systole (LVIDd and LVIDs, respectively), fractional shortening (FS), and ejection fraction (EF) were determined in short axis. Relative wall thickness (RWT) was calculated as: RWT = (SWTd+PWTd) / LVIDd. Tissue Doppler imaging (TDI) was performed in apical four chamber view with the sample volume at the septal annulus to assess early (E') and late (A') diastolic annular motion/velocity. PW Doppler was performed in the apical four-chamber view with the sample volume at the level of the LV mitral inflow tract for the determination of early (E) and late (A) transmitral peak diastolic flow velocity, isovolumic relaxation (IVRT) and contraction (IVCT) times, and ejection time (ET). Myocardial performance index (MPI), also known as the Tei index, was calculated as: (IVCT+IVRT) / ET. Finally, also in apical four chamber view, color M-mode recordings of mitral inflow during early diastole at the mitral leaflets were assessed to evaluate propagation velocity (Vp) of LV inflow, a correlate of the rate of chamber relaxation. All Doppler spectra were recorded across 5-8 cardiac cycles at a sweep speed of 200 mm/s and parameters were assessed in 3 cardiac cycles each from 3 different spectra. All data were collected and analyzed offline by a single observer.
Blood and urine chemistries. Blood glucose (AlphaTrak, Abbott) was determined immediately prior to euthanasia. Plasma total cholesterol and triglycerides, serum potassium, and urine protein, creatinine, and sodium were measured using an Olympus AU680 automated chemistry analyser (BeckmanCoulter, Brea, CA) and plasma insulin was determined using a rat-specific ELISA by a commercial laboratory (Comparative Clinical Pathology Services, Columbia, MO). Plasma aldosterone and corticosterone were determined in duplicate by RIA at the Vanderbilt Hormone Assay & Analytical Services Core (Nashville, TN). In addition, serum samples were assayed for leptin, monocyte chemotactic protein-1 (MCP-1) and tumor necrosis factor-α (TNF-α) using multiplex cytokine assays (Millipore Milliplex, Billerica, MA & Bio-Rad Bio-Plex Pro, Hercules, CA) on a MAGPIX instrument (Luminex), according to the manufacturer's instructions. Plasma renin activity was determined using a modification of the Sensolyte 520 Rat Renin Assay kit (Anaspec, Fremont, CA). Briefly, 90µl of plasma was combined with 10µl of diluted FRET-conjugated rat renin substrate (1:50 dilution). For kinetic measurement, fluorescence was measured with a Synergy H4 96-well plate reader (BioTek) at excitation/emission of 490/520 every 5 min for 60 min at 37°C. Plasma renin activity was assessed by the linear slope of the appearance of 5-carboxyfluorescein. Plasma angiotensin II concentration was determined by ELISA (Alpco Diagnostics, Salem, NH), according to manufacturer instructions.
Isolated coronary arterioles.
Following excision of the heart, the septum was removed and immediately placed in ice-cold physiological salt solution (PSS) containing (in mM): 145 NaCl, 4.7 KCl, 1.2 NaH 2PO4, 1.17 MgSO4, 2 CaCl2, 5 glucose, 2 pyruvate, 0.02 EDTA, 3 MOPS, and 1% bovine serum albumin, pH 7.4 (bubbling not necessary since pH buffered by MOPS). The left ventricular free wall was immediately frozen and stored at -80°C. Septal coronary arterioles (<200µm internal diameter) were isolated, cleaned, and secured to glass micropipettes, as previously described 8, 9 . Arterioles were visualized with an inverted microscope equipped with a calibrated video micrometer (Colorado Video, Boulder, CO) for the determination of internal diameter which was recorded using Chart software and a PowerLab data acquisition system (ADInstruments, Colorado Springs, CO). Arterioles were pressurized to 60cmH2O and those free from leaks were equilibrated for ~1 h, during which time the bath temperature was raised to 37°C and the PSS changed every 10-15 min. Arterioles were preconstricted to 25-40% tone with the thromboxane A2 analog U46619 for examination of dilator responses. Dilation to acetylcholine (ACh; 1 nM -10 mM), insulin (Novolin R, Novo Nordisk; 0.1 -100 ng/ml), and the nitric oxide (NO) donor sodium nitroprusside (SNP; 1 nM -10 mM) was assessed by cumulative addition of agonist to the vessel bath 10 . The doses of insulin utilized represent physiological (fasting ~0.2 ng/ml; post-prandial ~2 ng/ml), pathophysiological (>5 ng/ml) and pharmacological (>10 ng/ml) levels. In a separate set of experiments, the NO-dependent component of ACh dilation was determined by assessment of dilation to ACh following 20 min pretreatment with the NO synthase (NOS) inhibitor N Gnitro-L-arginine methyl ester (L-NAME; 300µM). The NOS contribution to ACh dilation was then determined by subtraction of the ACh response at each dose in the presence of L-NAME from the response to the corresponding dose in the absence of L-NAME in vessels from the same animal. Maximum passive diameter was determined at the end of the experiment for each vessel by replacement of the PSS with calcium-free PSS. In a subset of vessels, passive wall mechanics were determined with the vessel in calcium-free PSS. Passive mechanics were examined only after 80mM KCl challenge yielded no vasoconstriction. Experiments were performed and data was analyzed as previously described 11 . Young's elastic modulus was calculated as coronary arteriolar stress (α) / strain (ε). Coronary dilator responses are presented as percent maximal dilation, calculated as [(DdDb)/(Dmax -Db)] × 100, and constrictor responses are presented as percent vasoconstriction, calculated as [(Db -Dd)/Db] × 100 where Dd is diameter after a drug intervention, Db is baseline diameter, and Dmax is maximal passive diameter.
Aortic insulin stimulation. The thoracic aorta was removed, immediately placed in ice-cold PSS, and cleaned of surrounding tissue. Two 1.5-2 cm aortic sections were opened longitudinally, transferred to individual wells containing phenol-free DMEM plus 0.1% BSA, and incubated at 37°C for 2 h. Subsequently, one section was stimulated with insulin (100nM) for 30 min while the other section received vehicle, similar to a previous report 12 . Following stimulation, sections were pinned out lumenside up, Laemmli buffer containing protease and phosphatase inhibitors was applied and, using a sterile scalpel blade, the endothelial surface was mechanically scraped yielding an endotheliumenriched sample, as previously described 13 . Samples were immediately frozen and stored at -80°C until processed for immunoblotting.
Oxidative stress assays. Total cardiac reactive oxygen species (ROS) was determined by lucigeninenhanced chemiluminescence, as previously described 14 . Briefly, tissue sections were homogenized in sucrose buffer (250 mM sucrose, 0.5 mM EDTA, 50 mM HEPES, and protease inhibitor tablet, pH 7.5) and centrifuged at 1,500 relative centrifugal force for 10 min at 4°C. Whole homogenate (100 μl) was added to 1.4 ml of 50 mM phosphate (KH2PO4) buffer (150 mM sucrose, 1 mM EGTA, 5 μM lucigenin, and 100 μM NADPH, pH 7.0) in vials after 1 h of dark adaptation, samples were counted every 30 s for 10 min on a scintillation counter, and counts over the last 5 min were averaged. Superoxide production was calculated as relative lumens per second per milligram of fresh tissue for each sample after subtraction of the background activity. Because baseline ROS accumulation in ZL rats varied between the several cohorts, all data are expressed relative to ZL within each cohort.
Cardiac NADPH oxidase activity was determined according to established methods 14 . Briefly, aliquots of plasma membrane fractions containing 20 μg of protein were incubated with NADPH (100 mM) at 37°C. NADPH activity was determined by measurement of the conversion of Radical Detector (Cayman Chemical) in the absence and presence of the NADPH inhibitor diphenylene iodonium sulfate (500 μM) using spectrophotometric (450 nm) techniques. Data were calculated as milli-optical density units per minute and normalized to the protein content of the sample.
Cardiac and plasma lipid peroxide content was assessed in cardiac whole cell lysates using the thiobarbituric acid-reactive substance (TBARS) assay, according to manufacturer instructions (Zeptometrix Corp., Buffalo, NY).
RNA extraction and real-time PCR.
Cardiac and epididymal adipose tissue samples were frozen immediately at sacrifice and subsequently homogenized in TRIzol solution using a tissue homogenizer (TissueLyser LT, Qiagen, Valencia, CA). Total RNA was isolated using the Qiagen RNeasy Lipid Tissue Kit and assayed using a Nanodrop spectrophotometer (Thermo Scientific, Wilmington, DE) to assess purity and concentration. First-strand cDNA was synthesized from total RNA using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Carlsbad, CA). Quantitative real-time PCR was performed using the CFX Connect™ Real-Time PCR Detection System (BioRad, Hercules, CA). Primer sequences (Table S1 ) were designed using the NCBI Primer Design tool. All primers were purchased from IDT (Coralville, IA). A 20-μl reaction mixture containing 10 μl iTaq UniverSYBR Green SMX (BioRad, Hercules, CA) and the appropriate concentrations of gene-specific primers plus 4 μl of cDNA template were loaded in each well of a 96-well plate. All PCR reactions were performed in duplicate. PCR was performed with thermal conditions as follows: 95ºC for 10 min, followed by 40 cycles of 95ºC for 15 s and 60ºC for 45 s. A dissociation melt curve analysis was performed to verify the specificity of the PCR products. 18S and GAPDH primers were used to amplify the endogenous control product. In the present study, 18S and GAPDH CTs were not different among groups of animals within adipose and cardiac tissues. mRNA expression values were calculated as 2 ΔCT whereby ΔCT = 18S or GAPDH CT -gene of interest CT and are presented normalized to ZL or SD rats, which were set at 1.
Tissue staining, immunohistochemistry, and cardiomyocyte morphology. A portion of LV was immersion fixed in 3% paraformaldehyde, dehydrated in ethanol, paraffin embedded, and transversely sectioned in 5µm slices. Four sections each for 5-6 animals per group were examined. To evaluate cardiac fibrosis, as previously described 15 , sections were stained with picrosirius red (PR) and Verhoeff-von Gieson (VVG) stain for the determination of cardiac collagen and periarterial fibrosis, respectively. Staining was quantified as the average percent staining in 5 images per animal with the aid of the thresholding function in MetaVue software. Periarterial fibrosis was quantified as the average percent VVG staining of the vascular wall of coronary vessels. Cardiac oxidative stress was assessed by immunostaining for 3-nitrotyrosine (AB5411, Millipore), as previously described 15 . Briefly, 4 myocardial sections per animal were deparaffinized, rehydrated, and epitopes were retrieved in citrate buffer. Endogenous peroxidases and nonspecific binding were blocked with 3% H2O2 and avidin, biotin, and protein block, respectively. Sections were stained with primary antibody (1:200 dilution) overnight after which they were washed, incubated with secondary antibody, linked, labeled with streptavidin, and incubated with diaminobenzidine prior to staining with hematoxylin, rehydration, and mounting. Cardiomyocyte crosssectional area was determined from VVG stained sections captured in cross-section and crosssectional area was determined using Image J on cardiomyocytes with well-defined cellular membranes and visible nucleus, as previously described 1 . Approximately 15 cells from 2 separate sites were measured and averaged per group and area is expressed relative to the control group in each strain.
Immunoblotting. Left ventricular cardiac tissue was homogenized in lysis buffer containing protease and phosphatase inhibitors in a TissueLyser (Qiagen). Protein content of cardiac and aortic endothelial cell lysates were determined by BCA (Pierce) and Quant-iT (Invitrogen) protein assays, respectively. Cardiac samples were diluted in Laemmli buffer, 40µg protein was separated by 4-15% or 18% SDS-PAGE, transferred to nitrocellulose membranes, blocked with 5% non-fat milk in Tris-buffered salineTween 20 (TBST) solution and incubated overnight with gentle agitation at 4°C with anti-MCP-1 (1:1000, BD Pharmingen 551217) primary antibody. Three micrograms of aortic endothelium-enriched lysate was separated by 4-15% SDS-PAGE, transferred, blocked, and exposed to anti-Akt (1:500, Cell Signaling 9272), anti-phospho Akt (Thr 308 ,1:500, Cell Signaling 4056), and anti-pan-actin (1:1000, Cell Signaling 4968) antibodies as described for cardiac lysates. Membranes were subsequently incubated for 1 hr with appropriate secondary antibodies conjugated to horseradish peroxidase (1:20,000 or 1:30,000) and protein expression was detected by enhanced chemiluminescence (Pierce) on a Bio-Rad phosphoimager and quantified in Image Lab (Bio-Rad). Cardiac protein expression was normalized to total protein determined by Ponceau staining since preliminary experiments demonstrated group differences in cardiac actin expression. Actin expression was similar in aortic endothelial samples and aortic protein expression was normalized to actin. All antibodies were prepared in TBST containing 5% BSA.
Statistics. Data presented as means ± SE. Statistical analysis performed using Student's t test for planned comparisons, one-or two-way ANOVA with Fishers LSD post hoc analysis, as appropriate. A p value ≤0.05 was considered significant. SWTd, septal wall thickness-diastole; PWTd, posterior wall thickness-diastole; RWT, relative wall thickness; LVIDd, LV inner dimension-diastole; LVIDs, LV inner dimension-systole; EF, ejection fraction; FS, fractional shortening; LA, left atrial diameter; Ao, aortic diameter; A′, peak late septal annular velocity; E′, early peak septal annular velocity; IVRT, isovolumic relaxation time; E, velocity of early mitral inflow; E/E' index of LA filling pressure; E/Vp, index of LV filling pressure; MPI, myocardial performance index. Values are mean ± SE, N=8-10. *p<0.05 versus ZL; †p<0.05 versus ZO; §p=0.09 versus ZL; ¥p=0.06 versus ZL. 
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